Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2002

View Archived Issues

Three ZymoGenetics product candidates to enter clinic in the next year

Good safety profile reported for IL-13-PE38QQR in malignant glioma

Potential use of gabapentin in glossodynia

Neuroprotective effects reported for zanapezil in ischemic rats

Potential use of NO-releasing hydrogel dressing in wound healing

Induction of Th2 responses reported for rhIL-4 in psoriatic patients

Novel series of HIV reverse transcriptase inhibitors identified at Pfizer

Merck designs new NK1 antagonists

New amlodipine analogue with utility in angina and hypertension

Aeolus and Duke University claim porphyrin-based antioxidants for pulmonary inflammatory diseases

Novel ligands of G-protein-coupled receptors covered by Sepracor patent

Lilly and Boehringer Ingelheim sign cocommercialization agreements for duloxetine

Millennium to submit Velcade NDA and MAA filings by early 2003

huN901-DM1 enters phase II portion of U.S. SCLC study

Curis licenses PYY patents to Amylin for treatment of metabolic diseases

First phase III alvimopan trial in postoperative ileus completes enrollment

More obstacles to Pfizer/Pharmacia merger removed

Orphan drug status sought for thymosin beta 4

RSD-1235 shows oral bioavailability in humans

Once-weekly dosing of Enbrel supported by phase III study

IL-15-targeting antibody superior to ciclosporin in mouse model of psoriasis

Efalizumab suppresses inflammation-related genes in addition to T-cell migration

Civacir receives orphan drug status for prevention of hepatitis C

FDA requests additional clinical data for lercanidipine

Epimmune files IND for cancer vaccine

Novo Nordisk submits NDA for NN-304

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...